Screener
BioMarin Pharmaceuticals BMRN Q3 2026 earnings
Reported November 2, 2026 · After market close
Revenue$1.0BBeat by $2.3M
EPS$0.23Beat by $0.31
Revenue estimate$1.0B
EPS estimate-$0.08
“BioMarin delivered a strong quarter, with revenue growth of 32%, driven by a more diversified portfolio following the acquisition of Amicus Therapeutics earlier this year and increased demand for our medicines from patients around the world. For the first time, quarterly revenue exceeded $1 billion, a milestone for BioMarin. We are building on this achievement by continuing to expand our pipeline through focused business development. We are excited to add our newest asset, an investigational treatment for Fabry disease, which has the potential to become the first subcutaneous enzyme therapy for this condition. With this fourth new asset added to our pipeline in 2026, we are following through on our commitment to build sustainable growth for the future.”
Next report
Date not yet announcedValuation & ratios
Valuation
as of 11/02/26Versus estimates
Revenue
Diluted EPS
FAQ
- When did BioMarin Pharmaceuticals report Q3 2026 earnings?
- BioMarin Pharmaceuticals (BMRN) reported Q3 2026 earnings on November 2, 2026 after market close.
- What were BioMarin Pharmaceuticals's Q3 2026 revenue and EPS?
- BioMarin Pharmaceuticals reported revenue of $1.0B and eps of $0.23 for Q3 2026.
- Did BioMarin Pharmaceuticals beat estimates in Q3 2026?
- Revenue beat the consensus estimate of $1.0B by $2.3M. EPS beat the consensus estimate of $-0.08 by $0.31.
- How did BioMarin Pharmaceuticals's Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 32.0% from $776.1M a year earlier and eps grew 91.7% from $0.12.
- Where can I find BioMarin Pharmaceuticals's Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001048477-26-000021) directly on SEC EDGAR. The filing index links above go to sec.gov.
